Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Interim Statements of Operations (Unaudited)

v3.21.1
Condensed Consolidated Interim Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Mar. 31, 2021
Mar. 31, 2020
Expenses        
Research and development $ 3,843 $ 899 $ 7,784 $ 2,332
General and administrative 2,762 1,077 7,091 3,045
Merger costs     500  
In-process research and development     16,094  
Operating Expenses 6,605 1,976 31,469 5,377
Other (income) loss        
Foreign exchange 1 (2) 3  
Amortization of deferred loan costs 23   74  
Interest expense 7   23  
Interest income (1) (17) (3) (74)
Other loss (income) 30 (19) 97 (74)
Net loss for the period 6,635 1,957 31,566 5,303
Computation of basic loss per share        
Net loss for the period 6,635 1,957 31,566 5,303
Deemed dividend recognized on beneficial conversion features of Series C Preferred stock issuance     3,181  
Series A Preferred cash dividend 2 2 6 6
Series B Preferred stock dividend 6 1 15 6
Net loss for the period attributable to common stockholders $ 6,643 $ 1,960 $ 34,768 $ 5,315
Basic and fully diluted loss per share $ 0.23 $ 0.17 $ 1.47 $ 0.52
Basic and fully diluted weighted average number of shares 29,273,000 11,417,000 23,701,000 10,117,000